instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dizziness'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dysgeusia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspepsia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dysuria'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Flank pain'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fracture'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haematuria'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hydronephrosis'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertensive crisis'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypokalaemia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Insomnia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukopenia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lower urinary tract symptoms'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lymphopenia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Micturition urgency'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Musculoskeletal pain'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neck pain'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neuropathy peripheral'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oedema peripheral'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pain in extremity'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Paraesthesia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Persistent depressive disorder'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pollakiuria'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary embolism'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyelocaliectasis'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Radiculopathy'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Renal failure'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sciatica'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sleep disorder'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Spinal compression fracture'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Spinal cord compression'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Stomatitis'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Upper gastrointestinal haemorrhage'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urinary incontinence'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urinary retention'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Weight decreased'. | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | ABIRATERONE ACETATE, ENZALUTAMIDE, PREDNISOLONE | DrugsGivenReaction | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the administration route of drug 'ABIRATERONE ACETATE'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Oral | DrugAdministrationRoute | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the administration route of drug 'ENZALUTAMIDE'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Oral | DrugAdministrationRoute | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the administration route of drug 'PREDNISOLONE'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Oral | DrugAdministrationRoute | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the dosage of drug 'ABIRATERONE ACETATE'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | 1000 mg (milligrams). | DrugDosage | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the dosage of drug 'ENZALUTAMIDE'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | 160 mg (milligrams). | DrugDosage | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the dosage of drug 'PREDNISOLONE'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | 10 mg (milligrams). | DrugDosage | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the outcome of reaction 'Acute coronary syndrome'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Fatal | ReactionOutcome | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the outcome of reaction 'Cardiac failure'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Fatal | ReactionOutcome | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the outcome of reaction 'Hypertensive crisis'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Fatal | ReactionOutcome | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the outcome of reaction 'Pulmonary embolism'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Fatal | ReactionOutcome | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the outcome of reaction 'Sepsis'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Fatal | ReactionOutcome | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the outcome of reaction 'Spinal compression fracture'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Fatal | ReactionOutcome | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
What was the outcome of reaction 'Upper gastrointestinal haemorrhage'? | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
BACKGROUND
In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalu... | Fatal | ReactionOutcome | CC BY-NC | 33738495 | 17,366,432 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal sepsis'. | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | AURANOFIN, ETHAMBUTOL HYDROCHLORIDE, ISONIAZID, PYRAZINAMIDE, PYRIDOXINE, RIFABUTIN | DrugsGivenReaction | CC BY | 33740465 | 19,154,356 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disseminated intravascular coagulation'. | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | AURANOFIN, ETHAMBUTOL HYDROCHLORIDE, ISONIAZID, PYRAZINAMIDE, PYRIDOXINE, RIFABUTIN | DrugsGivenReaction | CC BY | 33740465 | 19,154,356 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug-induced liver injury'. | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | ETHAMBUTOL HYDROCHLORIDE, ISONIAZID, PYRAZINAMIDE, PYRIDOXINE, RIFABUTIN | DrugsGivenReaction | CC BY | 33740465 | 19,159,768 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastroenteritis'. | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | AURANOFIN, ETHAMBUTOL HYDROCHLORIDE, ISONIAZID, PYRAZINAMIDE, PYRIDOXINE, RIFABUTIN | DrugsGivenReaction | CC BY | 33740465 | 19,154,356 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypotension'. | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | AURANOFIN, ETHAMBUTOL HYDROCHLORIDE, ISONIAZID, PYRAZINAMIDE, PYRIDOXINE, RIFABUTIN | DrugsGivenReaction | CC BY | 33740465 | 19,154,356 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory failure'. | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | AURANOFIN, ETHAMBUTOL HYDROCHLORIDE, ISONIAZID, PYRAZINAMIDE, PYRIDOXINE, RIFABUTIN | DrugsGivenReaction | CC BY | 33740465 | 19,154,356 | 2021-08 |
What was the administration route of drug 'AURANOFIN'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Oral | DrugAdministrationRoute | CC BY | 33740465 | 19,154,356 | 2021-08 |
What was the administration route of drug 'ETHAMBUTOL HYDROCHLORIDE'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Oral | DrugAdministrationRoute | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the administration route of drug 'ISONIAZID'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Oral | DrugAdministrationRoute | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the administration route of drug 'PYRAZINAMIDE'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Oral | DrugAdministrationRoute | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the administration route of drug 'PYRIDOXINE'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Oral | DrugAdministrationRoute | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the administration route of drug 'RIFABUTIN'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Oral | DrugAdministrationRoute | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the dosage of drug 'ETHAMBUTOL HYDROCHLORIDE'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | UNK, DAILY | DrugDosageText | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the dosage of drug 'ISONIAZID'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | UNK, DAILY | DrugDosageText | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the dosage of drug 'PYRAZINAMIDE'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | UNK, DAILY | DrugDosageText | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the dosage of drug 'PYRIDOXINE'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | UNK, DAILY | DrugDosageText | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the outcome of reaction 'Abdominal sepsis'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Fatal | ReactionOutcome | CC BY | 33740465 | 19,154,356 | 2021-08 |
What was the outcome of reaction 'Disseminated intravascular coagulation'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Fatal | ReactionOutcome | CC BY | 33740465 | 19,154,356 | 2021-08 |
What was the outcome of reaction 'Drug-induced liver injury'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Recovered | ReactionOutcome | CC BY | 33740465 | 19,159,768 | 2021-08 |
What was the outcome of reaction 'Gastroenteritis'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Fatal | ReactionOutcome | CC BY | 33740465 | 19,154,356 | 2021-08 |
What was the outcome of reaction 'Hypotension'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Fatal | ReactionOutcome | CC BY | 33740465 | 19,154,356 | 2021-08 |
What was the outcome of reaction 'Respiratory failure'? | Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
Current tuberculosis treatments leave patients with clinically significant lung injury and increased all-cause mortality post-cure. Adjunctive host-directed therapies could protect the lungs, ... | Fatal | ReactionOutcome | CC BY | 33740465 | 19,154,356 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal discomfort'. | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | CEFTAZIDIME, CEFTRIAXONE, CIPROFLOXACIN, DEXAMETHASONE, LINEZOLID, MEROPENEM, METRONIDAZOLE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | CEFTAZIDIME, CEFTRIAXONE, CIPROFLOXACIN, DEXAMETHASONE, LINEZOLID, MEROPENEM, METRONIDAZOLE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | CEFTAZIDIME, CEFTRIAXONE, CIPROFLOXACIN, DEXAMETHASONE, LINEZOLID, MEROPENEM, METRONIDAZOLE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Headache'. | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | CEFTAZIDIME, CEFTRIAXONE, CIPROFLOXACIN, DEXAMETHASONE, LINEZOLID, MEROPENEM, METRONIDAZOLE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic enzyme increased'. | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | CEFTAZIDIME, CEFTRIAXONE, CIPROFLOXACIN, DEXAMETHASONE, LINEZOLID, MEROPENEM, METRONIDAZOLE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | CEFTAZIDIME, CEFTRIAXONE, CIPROFLOXACIN, DEXAMETHASONE, LINEZOLID, MEROPENEM, METRONIDAZOLE, SULFAMETHOXAZOLE\TRIMETHOPRIM | DrugsGivenReaction | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
What is the weight of the patient? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | 90 kg. | Weight | CC BY | 33740906 | 19,188,994 | 2021-03-19 |
What was the administration route of drug 'CEFTAZIDIME'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33740906 | 19,188,994 | 2021-03-19 |
What was the administration route of drug 'CIPROFLOXACIN'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | Oral | DrugAdministrationRoute | CC BY | 33740906 | 19,206,005 | 2021-03-19 |
What was the administration route of drug 'DEXAMETHASONE'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33740906 | 19,179,620 | 2021-03-19 |
What was the administration route of drug 'SULFAMETHOXAZOLE\TRIMETHOPRIM'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | Oral | DrugAdministrationRoute | CC BY | 33740906 | 19,206,005 | 2021-03-19 |
What was the dosage of drug 'MEROPENEM'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | 1 GRAM, TID | DrugDosageText | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
What was the outcome of reaction 'Abdominal discomfort'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | Recovered | ReactionOutcome | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
What was the outcome of reaction 'Decreased appetite'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | Recovered | ReactionOutcome | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
What was the outcome of reaction 'Headache'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | Recovered | ReactionOutcome | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
What was the outcome of reaction 'Hepatic enzyme increased'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | Recovered | ReactionOutcome | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
What was the outcome of reaction 'Pyrexia'? | Thalamic abscess in a patient with hereditary hemorrhagic telangiectasia successfully treated with an empiric antibiotic regime: case report and review of the literature.
BACKGROUND
Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease associated with neurological complications, including cer... | Recovered | ReactionOutcome | CC BY | 33740906 | 20,453,581 | 2021-03-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumomediastinum'. | New insights in phenotype and treatment of lung disease immuno-deficiency and chromosome breakage syndrome (LICS).
We report five patients with lung disease immuno-deficiency and chromosome breakage syndrome (LICS) but without recurrent infections and severe immunodeficiency. One patient had extended survival to 6.5 ye... | DEXAMETHASONE | DrugsGivenReaction | CC BY | 33741030 | 19,164,086 | 2021-03-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumothorax'. | New insights in phenotype and treatment of lung disease immuno-deficiency and chromosome breakage syndrome (LICS).
We report five patients with lung disease immuno-deficiency and chromosome breakage syndrome (LICS) but without recurrent infections and severe immunodeficiency. One patient had extended survival to 6.5 ye... | DEXAMETHASONE | DrugsGivenReaction | CC BY | 33741030 | 19,164,086 | 2021-03-19 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.